Taysha Gene Therapies (NASDAQ:TSHA) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note published on Monday,Benzinga reports. The firm currently has a $6.00 price target on the stock.

Several other equities analysts have also recently issued reports on TSHA. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Finally, JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Trading Up 2.7 %

Shares of Taysha Gene Therapies stock opened at $1.93 on Monday. The firm has a market cap of $395.54 million, a price-to-earnings ratio of 3.06 and a beta of 0.95. Taysha Gene Therapies has a 52-week low of $1.19 and a 52-week high of $4.32. The company’s 50-day simple moving average is $2.10 and its 200-day simple moving average is $2.14. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Institutional Trading of Taysha Gene Therapies

Institutional investors have recently bought and sold shares of the company. Creative Planning purchased a new position in shares of Taysha Gene Therapies in the third quarter valued at $28,000. Principal Financial Group Inc. purchased a new position in Taysha Gene Therapies in the second quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. lifted its position in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after buying an additional 17,446 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Taysha Gene Therapies during the third quarter worth approximately $85,000. Finally, Scientech Research LLC acquired a new stake in shares of Taysha Gene Therapies in the second quarter worth $97,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.